Health Canada has granted approval for GlaxoSmithKline’s ( GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Welcome to Natera’s 2024 Third Quarter Financial Results ...
Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...
Y-o-Y Growth and Strong Performance in 2024 The Small Molecule API market is anticipated to exhibit a Y-o-Y growth of 4.6% in ...